What is YolTech Therapeutics?
YolTech Therapeutics is at the forefront of developing innovative in vivo gene-editing therapies, aiming to provide one-time curative treatments. The company has established a comprehensive, integrated platform that includes its proprietary CRISPR nucleases, known as YolCas, and base editors, YolBE. Complementing these gene-editing tools is a state-of-the-art lipid nanoparticle delivery system, Yol-LNPs, engineered for precise, efficient, and tissue-specific gene editing across a wide spectrum of therapeutic applications.
How much funding has YolTech Therapeutics raised?
YolTech Therapeutics has raised a total of $45M across 1 funding round:
Series B
$45M
Series B (2025): $45M with participation from AstraZeneca
Key Investors in YolTech Therapeutics
AstraZeneca
AstraZeneca, a global biopharmaceutical company, focuses on the discovery, development, and commercialization of prescription medicines, particularly in Oncology and BioPharmaceuticals. Their involvement suggests a strategic interest in YolTech's therapeutic applications within established or emerging disease areas.
What's next for YolTech Therapeutics?
With substantial enterprise-level funding and a recent strategic investment, YolTech Therapeutics is well-positioned for significant expansion and the acceleration of its clinical development pipeline. The company's focus on a fully integrated platform, from proprietary editing tools to advanced delivery systems, suggests a strategic direction towards overcoming key challenges in gene therapy delivery and efficacy. Future endeavors will likely concentrate on advancing its lead candidates through clinical trials, potentially forging strategic partnerships to broaden market access, and further refining its technology for diverse genetic disorders.
See full YolTech Therapeutics company page
